Medigen Vaccine Biologics SARS-CoV-2 qPCR kit obtained CE Marking and Taiwan MOHW’s approval of specific medical device’s manufacturing

, , ,

On Apr. 30, 2020, Medigen Vaccine Biologics (MVB) complied with EU CE requirements, completed the EU declaration of conformity and obtained CE marking (IVD) on April 24th.

In addition, MVC applied for specific medical devices’ manufacturing in Taiwan according to Pharmaceutical Affairs Act and obtained Taiwan MOHW’s approval on April 30th.

This qPCR Kit can directly test upper/lower respiratory tract specimens which reduce laboratories’ extra preparation time and manpower. It is limited to the use of domestic laboratories accredited by Taiwan CDC during the approved manufacturing period until the dissolution of the Central Epidemic Command Center.

Tags:


Source: Medigen Vaccine Biologics
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.